Return to Listing

3 result(s) for Vidaza

PI Name Protocol # Title
Emma Scott STUDY00015214 A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies
Laura Newell STUDY00015619 A phase 1/2 study of Vadastuximab Talirine (SGN-CD33A) in combination with Azacitidine in patients with previously untreated international prognostic scoring system (IPSS) intermediate -2 or high-risk Myelodysplastic Syndrome (MDS).
Kim-Hien Dao STUDY00016964 A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

You may also qualify for Phase 1 Program trials.

For more information:
Call: 503-494-1080